11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention
Key Takeaways
- Pediatric DKA is diagnostically defined by blood glucose >200 mg/dL (>11.1 mmol/L), venous pH <7.30 or serum bicarbonate <15 mEq/L, and confirmed ketonemia (serum beta-hydroxybutyrate ≥3.0 mmol/L) or ketonuria; severity is stratified by venous pH and bicarbonate into mild (pH 7.20–7.29, bicarb 10–14), moderate (pH 7.10–7.19, bicarb 5–9), and severe (pH <7.10, bicarb <5).
- Initial fluid resuscitation requires 10–20 mL/kg of isotonic crystalloid (0.9% NaCl or balanced crystalloid) over 30–60 minutes, followed by deficit replacement calculated over 24–48 hours (typically 48 hours in moderate-to-severe DKA); total rehydration rates must strictly not exceed 1.5 to 2.0 times maintenance fluids to prevent precipitous drops in effective serum osmolality.
- Initial intravenous insulin boluses are strictly contraindicated in pediatric DKA due to dramatic increases in cerebral edema risk and sudden hypokalemia; continuous regular insulin infusion at 0.05–0.1 units/kg/hr must be initiated 1 to 2 hours AFTER fluid resuscitation has begun.
- Potassium replacement (20–40 mEq/L, administered as 50% KCl and 50% KPO4) must be added to maintenance fluids once urine output is documented and serum potassium is <5.5 mEq/L; conversely, sodium bicarbonate therapy is strongly contraindicated due to paradoxical central nervous system (CSF) acidosis, worsening intracellular hypokalemia, and a >4-fold increase in cerebral edema odds.
- DKA-related cerebral edema must be treated immediately upon neurological deterioration without waiting for cranial imaging: administer hypertonic 3% sodium chloride (2.5–5 mL/kg IV over 10–15 min) or 20% mannitol (0.5–1.0 g/kg IV over 20 min), elevate the head of bed to 30 degrees, and reduce fluid infusion rates by one-third to one-half.
11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention
Diabetic Ketoacidosis (DKA) is the leading cause of morbidity and mortality in pediatric patients with type 1 diabetes mellitus. The overwhelming majority of deaths (approx. 60% to 90%) in pediatric DKA are directly attributable to DKA-related cerebral edema / acute brain injury. Managing pediatric DKA requires a disciplined, evidence-based approach that addresses profound dehydration, severe high anion gap metabolic acidosis, and massive electrolyte depletion while scrupulously avoiding therapeutic interventions that precipitate rapid intracranial osmolar shifts.
Diagnostic Criteria & Severity Stratification
According to consensus guidelines from the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the Pediatric Emergency Care Applied Research Network (PECARN), pediatric DKA is diagnosed by the biochemical triad of:
- Hyperglycemia: Blood glucose > 200 mg/dL (> 11.1 mmol/L).
- Metabolic Acidosis: Venous blood gas pH < 7.30 or serum bicarbonate < 15 mEq/L.
- Ketosis: Ketonemia (serum beta-hydroxybutyrate [BOHB] ≥ 3.0 mmol/L) or moderate-to-large ketonuria.
ISPAD Pediatric DKA Severity Staging & Biochemical Markers:
┌─────────────────┬────────────────────┬──────────────────────┬─────────────────────────┐
│ Severity Stage │ Venous Blood pH │ Serum Bicarbonate │ Clinical Presentation │
├─────────────────┼────────────────────┼──────────────────────┼─────────────────────────┤
│ MILD DKA │ 7.20 to 7.29 │ 10 to 14 mEq/L │ Alert, mild dehydration │
│ MODERATE DKA │ 7.10 to 7.19 │ 5 to 9 mEq/L │ Kussmaul breathing, dry │
│ SEVERE DKA │ < 7.10 │ < 5 mEq/L │ Somnolence, severe loss │
└─────────────────┴────────────────────┴──────────────────────┴─────────────────────────┘
Essential Diagnostic Formulas in DKA Evaluation
- Effective Serum Osmolality: Evaluates true intravascular tonicity (excluding urea, which diffuses freely across cell membranes):
- Corrected Serum Sodium: Severe hyperglycemia exerts an osmotic draw that shifts water from the intracellular to extracellular space, diluting measured sodium. Sodium must be corrected to assess true hydration state: (Note: A failure of measured sodium to rise progressively as serum glucose declines during therapy is a cardinal warning sign of impending cerebral edema).
- Serum Anion Gap: Confirms high anion gap ketoacidosis: In pediatric DKA, the anion gap typically ranges from 20 to >35 mEq/L.
Pathophysiology of DKA & Cerebral Edema Risk Factors
Pathophysiologic Cascade of Pediatric DKA & Cerebral Edema:
Absolute Insulin Deficiency + Counterregulatory Surge (Glucagon, Cortisol, Epinephrine, GH)
│
┌───────────────────────────┴───────────────────────────┐
▼ ▼
Unchecked Lipolysis (FFA Release) Accelerated Glycogenolysis &
│ Hepatic Gluconeogenesis
▼ │
Hepatic Ketogenesis (Acetoacetate & BOHB) ▼
│ Severe Hyperglycemia (>200-500 mg/dL)
▼ │
High Anion Gap Metabolic Acidosis ▼
(pH <7.30, HCO3 <15 mEq/L) Osmotic Diuresis & Electrolyte Wasting
│ (Water, Na+, K+, PO4, Mg2+ loss)
│ │
▼ ▼
Kussmaul Breathing (Hypocapnia) Severe Hypovolemia & Prerenal Azotemia
│ │
└───────────────────────────┬───────────────────────────┘
│
▼
CEREBRAL EDEMA / BRAIN INJURY TRIGGERS:
• Intracranial ischemia-reperfusion injury during aggressive rehydration
• Rapid drop in effective osmolality (>3 mOsm/kg/hr)
• Administration of IV insulin bolus (sudden oncotic shift)
• Administration of sodium bicarbonate (paradoxical CSF acidosis)
• Excessive fluid volumes (>4 L/m2/day or >2× maintenance)
Mechanisms of Pediatric Cerebral Edema
DKA-related acute brain injury develops in 0.5% to 1.0% of pediatric DKA episodes, carrying a 20% to 25% mortality rate and leaving 20% to 35% of survivors with permanent neurological sequelae. Pathophysiology involves two interacting mechanisms:
- Vasogenic Edema & Neuroinflammation: Cerebral hypoperfusion and severe acidosis induce endothelial activation, microglial activation, and disruption of the blood-brain barrier.
- Cytotoxic Edema & Osmotic Shifts: Brain cells accumulate intracellular organic osmolytes (taurine, myoinositol, betaine) to maintain cell volume during prolonged hyperosmolality. If plasma effective osmolality drops precipitously during treatment (due to rapid hypotonic fluid administration or sudden insulin bolusing), water moves rapidly down its osmotic gradient into brain astrocytes, triggering cellular swelling, elevated intracranial pressure, and transtentorial herniation.
Clinical Risk Factors for Cerebral Edema (PECARN / ISPAD Criteria)
- Patient-Specific Factors: Younger age (< 5 years), new-onset T1DM, longer duration of symptoms, greater degree of dehydration, higher baseline BUN, severe initial acidosis (venous pH < 7.10, HCO3 < 5 mEq/L), and severe hypocapnia (pCO2 < 18–20 mmHg).
- Iatrogenic / Treatment-Related Factors:
- Administration of an initial intravenous insulin bolus.
- Starting insulin infusion before initiating fluid resuscitation.
- Excessive fluid administration in the first 4 to 24 hours (> 4 L/m2/day or > 2× maintenance).
- Rapid decline in effective serum osmolality (> 3 mOsm/kg/hr).
- Administration of sodium bicarbonate.
Fluid Resuscitation & The Two-Bag Method
Fluid therapy in pediatric DKA aims to restore effective circulating blood volume, improve glomerular filtration to facilitate glucose and ketoacid clearance, and replace fluid deficits gradually over 24 to 48 hours.
Fluid Resuscitation & Replacement Timeline in Pediatric DKA:
Step 1: INITIAL VOLUME EXPANSION (0 to 60 Minutes)
• 0.9% NaCl or Plasmalyte: 10 - 20 mL/kg IV over 30 - 60 minutes
• Infuse only to restore peripheral perfusion; repeat ONLY if patient in hypotensive shock
• (Do not exceed 20-30 mL/kg in total initial boluses)
Step 2: DEFICIT & MAINTENANCE CALCULATION (Over 24 to 48 Hours)
• Moderate DKA: Assume 5 - 7% dehydration deficit
• Severe DKA: Assume 7 - 10% dehydration deficit
• Total Deficit (mL) = % Dehydration × Weight (kg) × 1000 mL/kg (minus initial bolus)
• Deficit replacement spread evenly over 48 HOURS
• Hourly Rate = (Deficit - Initial Bolus) / 48 hr + Hourly Maintenance Rate
• STRICT CEILING: Total hourly fluid rate must NOT exceed 1.5 to 2.0 × Maintenance
Step 3: TWO-BAG FLUID METHOD (Initiated when BG reaches 250 - 300 mg/dL)
• Maintains constant fluid and electrolyte infusion while adjusting dextrose concentration
The Two-Bag Fluid System
To prevent sudden fluctuations in serum glucose and osmolality while maintaining a steady insulin infusion, modern pediatric centers utilize the Two-Bag System:
The Two-Bag Fluid System Diagram:
BAG 1 (Dextrose-Free): BAG 2 (High Dextrose):
0.45% or 0.9% NaCl 0.45% or 0.9% NaCl
+ 20-40 mEq/L Potassium + 20-40 mEq/L Potassium
(50% KCl / 50% KPO4) (50% KCl / 50% KPO4)
+ 0% DEXTROSE (D0W) + 10% DEXTROSE (D10W)
│ │
└───────────────────────┬───────────────────────┘
▼
Y-Site Infusion via Smart Pump
│
▼
Delivers CONSTANT total fluid rate (mL/hr)
Delivers CONSTANT electrolyte concentration
Dextrose titrated dynamically (0% to 10%)
- Operation: When blood glucose drops to 250 to 300 mg/dL (or if glucose falls faster than 50 to 100 mg/dL/hr), Bag 2 is titrated upward and Bag 1 downward. The total combined hourly rate remains unchanged, but dextrose concentration increases (D2.5, D5, D7.5, D10) to clamp blood glucose between 150 and 200 mg/dL (8.3–11.1 mmol/L) while the insulin infusion continues unhindered to clear ketoacidosis.
Insulin Administration Protocol
Insulin Therapy Protocol in Pediatric DKA:
┌─────────────────────────────────────────────────────────────────────────────┐
│ CRITICAL BCPPS EXAM SAFETY RULES: │
│ │
│ 1. NEVER ADMINISTER AN INITIAL IV INSULIN BOLUS! │
│ (Boluses cause rapid drops in osmolality and trigger cerebral herniation)│
│ │
│ 2. START CONTINUOUS REGULAR INSULIN INFUSION AT 0.05 TO 0.1 UNITS/KG/HR │
│ (0.05 units/kg/hr for mild/moderate or young children; 0.1 for severe) │
│ │
│ 3. START INSULIN 1 TO 2 HOURS AFTER FLUID RESUSCITATION HAS BEGUN │
│ (Allows volume expansion and prevents sudden hemodynamic collapse) │
│ │
│ 4. DO NOT DECREASE INSULIN DOSE WHEN GLUCOSE REACHES 250 MG/DL! │
│ (Add dextrose via Two-Bag system; insulin is required to shut off │
│ lipolysis and resolve acidosis, not merely to lower blood glucose) │
└─────────────────────────────────────────────────────────────────────────────┘
- Formulation: Regular human insulin (U-100 regular insulin 1 unit/mL or 0.1 unit/mL in 0.9% NaCl). Tubing must be flushed with 20–50 mL of insulin solution prior to connecting to saturate non-specific plastic binding sites.
- Dosing: Initiate at 0.05 to 0.1 units/kg/hr without an initial bolus. A rate of 0.05 units/kg/hr is non-inferior to 0.1 units/kg/hr in time to acidosis resolution while carrying significantly lower rates of hypokalemia and hypoglycemia.
Potassium & Phosphate Management
Total-body potassium depletion in pediatric DKA is severe (3 to 5 mEq/kg), driven by urinary potassium wasting from osmotic diuresis and secondary hyperaldosteronism. However, initial serum potassium levels are frequently normal or elevated due to extracellular shifts caused by insulin deficiency and metabolic acidosis.
Potassium Replacement Decision Algorithm:
Initial Serum K+ ≥ 5.5 mEq/L: Initial Serum K+ 3.5 - 5.5 mEq/L: Initial Serum K+ < 3.5 mEq/L:
┌────────────────────────────┐ ┌────────────────────────────┐ ┌────────────────────────────┐
│ • Do NOT add K+ to fluids │ │ • Add 20 - 40 mEq/L K+ │ │ • DELAY INSULIN INFUSION! │
│ • Re-check K+ every 1-2 hr │ │ to IV maintenance fluids │ │ • Administer IV potassium │
│ • Confirm urine output │ │ • Confirm urine output │ │ at 0.5 - 1.0 mEq/kg/hr │
│ • Add K+ once K+ <5.5 │ │ • Blend 50% KCl / 50% KPO4 │ │ • Start insulin ONLY when │
│ and urine is documented │ │ • Prevents hyperchloremia │ │ serum K+ rises > 3.5 │
└────────────────────────────┘ └────────────────────────────┘ └────────────────────────────┘
- Potassium Composition: The recommended 20 to 40 mEq/L of potassium should be supplied as an equimolar combination of potassium chloride (50%) and potassium phosphate (50%) (or potassium acetate). Administering replacement solely as potassium chloride induces severe hyperchloremic metabolic acidosis, which delays bicarbonate normalization, clouding assessment of DKA resolution.
- Hypophosphatemia Caution: Severe hypophosphatemia (< 1.5 mg/dL) can precipitate encephalopathy, acute respiratory muscle weakness, diaphragmatic fatigue, and rhabdomyolysis. Supplying phosphate via potassium phosphate prevents these complications.
Why Sodium Bicarbonate is Strictly Contraindicated
Despite severe acidemia (pH < 7.10), randomized trials and consensus guidelines universally condemn the routine administration of sodium bicarbonate in pediatric DKA. Bicarbonate fails to accelerate clinical recovery and introduces catastrophic physiological hazards:
The Paradoxical Central Nervous System (CSF) Acidosis Mechanism:
Systemic Administration of Exogenous Sodium Bicarbonate (NaHCO3)
│
▼
NaHCO3 + H+ (circulating) ──► H2CO3 ──► H2O + CO2 (gas)
│
┌──────────────────────────────────────┴──────────────────────────────────────┐
▼ ▼
HCO3- Ion (Charged, Polar) CO2 Molecule (Lipophilic)
│ │
▼ ▼
CROSSES BLOOD-BRAIN BARRIER CROSSES BLOOD-BRAIN BARRIER
VERY SLOWLY & POORLY FREELY & RAPIDLY
│ │
▼ ▼
Minimal CSF alkalinization Diffuses into CSF within seconds
│
▼
CO2 + H2O ──► H2CO3 ──► H+ + HCO3-
│
▼
PARADOXICAL DROP IN CSF pH
(Worsens Brain Acidosis & Coma)
- Paradoxical CNS Acidosis: Bicarbonate combines with blood protons to generate carbon dioxide ($CO_2$). Because $CO_2$ is highly lipid-soluble, it diffuses across the blood-brain barrier instantly. In cerebrospinal fluid, it re-hydrates to carbonic acid, releasing free hydrogen ions and driving CSF pH downward, worsening cerebral depression.
- Exacerbation of Hypokalemia: Bicarbonate drives extracellular potassium into cells, precipitating sudden cardiac dysrhythmias.
- Impaired Tissue Oxygen Delivery: Alkalinization shifts the oxyhemoglobin dissociation curve to the left (Bohr effect), increasing hemoglobin-oxygen affinity and impairing peripheral and cerebral oxygen extraction.
- Proven Cerebral Edema Association: The landmark PECARN multivariable analyses revealed that bicarbonate administration was independently associated with an odds ratio of 4.2 for developing clinical cerebral edema.
- Only Extreme Exceptions: Severe life-threatening hyperkalemia with broad QRS complexes or profound circulatory collapse refractory to fluid resuscitation.
Cerebral Edema Surveillance & Emergency Pharmacotherapy
Bedside neurological evaluations (using the Glasgow Coma Scale [GCS] and pediatric pupillary reflexes) must be performed hourly during the first 12 to 24 hours of DKA therapy.
Clinical Diagnostic Criteria for Cerebral Edema
- Major Signs: Abnormal motor or verbal response to pain; decorticate or decerebrate posturing; cranial nerve palsy (especially abducens [CN VI] nerve palsy with diplopia or failure of lateral gaze); abnormal central neurogenic respiratory pattern (Cheyne-Stokes, tachypneic apneas).
- Minor Signs: Lethargy or difficulty being awakened; persistent headache; intractable vomiting; sudden decrease in GCS ≥ 2 points; Cushing's Triad (bradycardia, hypertension, irregular respirations).
Cerebral Edema Emergency Bedside Action Protocol:
1. DO NOT WAIT FOR CT SCAN! Brain herniation can occur within minutes. Initiate Rx immediately.
2. HYPERTONIC 3% SODIUM CHLORIDE:
• Dose: 2.5 to 5 mL/kg IV infused over 10 to 15 minutes
• Preferred agent in pediatrics: restores intravascular sodium, avoids osmotic diuresis
• May repeat in 30 minutes if no clinical neurological improvement
3. MANNITOL (20% Solution):
• Dose: 0.5 to 1.0 g/kg IV infused over 20 minutes (2.5 to 5 mL/kg of 20% solution)
• May repeat in 30 to 120 minutes if needed
4. ADJUNCTIVE PICU MEASURES:
• Elevate head of bed to 30 degrees (promotes intracranial venous drainage)
• Immediately REDUCE total IV fluid infusion rate by 30% to 50%
• Avoid routine endotracheal intubation unless acute respiratory arrest; maintain pCO2 30-35 mmHg
(Aggressive hyperventilation to pCO2 <25 mmHg causes severe cerebral vasoconstriction & ischemia)
DKA Resolution & Subcutaneous Insulin Transition
Criteria for DKA Resolution
DKA is resolved when all the following biochemical parameters are met:
- Venous blood gas pH > 7.30 or serum bicarbonate ≥ 15 to 18 mEq/L.
- Normal serum anion gap (≤ 12 mEq/L).
- Serum beta-hydroxybutyrate < 1.0 mmol/L.
- Resolution of nausea, emesis, and the patient is alert and tolerating oral intake.
Subcutaneous Transition Protocol
- Timing of Subcutaneous Dosing: Subcutaneous basal insulin (or a combined basal and rapid-acting dose administered with a meal) must be administered 15 to 30 minutes (with rapid-acting) or 2 to 3 hours (with basal glargine/degludec) BEFORE the continuous intravenous insulin infusion is turned off.
- Clinical Trap: Never abruptly shut off the intravenous regular insulin infusion without prior subcutaneous coverage. Intravenous regular insulin has an elimination half-life of only 4 to 5 minutes; stopping the infusion without circulating subcutaneous insulin depots results in rapid rebound hyperglycemia, acute lipolysis, and recurrent ketoacidosis within 30 to 60 minutes.
A 6-year-old child (weight 20 kg) presents to the pediatric emergency department with new-onset type 1 diabetes. Laboratory evaluation reveals: point-of-care blood glucose 480 mg/dL, venous blood gas pH 7.08, serum bicarbonate 6 mEq/L, serum beta-hydroxybutyrate 5.8 mmol/L, serum potassium 4.2 mEq/L, and BUN 28 mg/dL. The child is alert but tachypneic with Kussmaul respirations. In accordance with ISPAD and PECARN pediatric DKA guidelines, which initial therapeutic intervention is strictly contraindicated?
A 9-year-old child being treated in the pediatric intensive care unit for severe DKA (initial venous pH 7.04, bicarbonate 4 mEq/L) has been receiving 0.9% NaCl with 30 mEq/L potassium at 1.5 times maintenance and regular insulin at 0.1 units/kg/hr. Four hours into therapy, the bedside nurse reports that the patient has developed a severe bifrontal headache, has vomited twice, exhibits a heart rate falling from 112 to 56 beats/min, and blood pressure rising from 104/62 to 142/88 mmHg. The patient's Glasgow Coma Scale (GCS) score has fallen from 15 to 11. Which immediate management plan must be executed?
A pediatric clinical specialist is managing a 12-year-old patient with DKA who has been receiving continuous regular insulin infusion at 0.1 units/kg/hr. After 14 hours of therapy, laboratory results demonstrate: venous blood gas pH 7.34, serum bicarbonate 19 mEq/L, serum sodium 138 mEq/L, chloride 107 mEq/L, potassium 4.1 mEq/L, beta-hydroxybutyrate 0.7 mmol/L, and blood glucose 165 mg/dL. The calculated anion gap is 12 mEq/L. The patient is alert, hungry, and tolerating oral sips of water. What is the most appropriate protocol for transitioning this patient to subcutaneous insulin therapy?